Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer

PURPOSE: Gonadotropin-releasing hormone (GnRH) agonists decrease bone mineral density (BMD) and increase fracture risk in men with prostate cancer. Annual zoledronic acid increases BMD in postmenopausal women, but its efficacy in hypogonadal men is not known. PATIENTS AND METHODS: In a 12-month stud...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Michaelson, M. Dror, Kaufman, Donald S., Lee, Hang, McGovern, Francis J., Kantoff, Philip W., Fallon, Mary Anne, Finkelstein, Joel S., Smith, Matthew R.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2007
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3047397/
https://ncbi.nlm.nih.gov/pubmed/17369566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2006.07.3361
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים